LIFE aTyr Pharma Inc.

3.41
-0.03  -1%
Previous Close 3.44
Open 3.44
Price To Book 0.44
Market Cap 13,265,531
Shares 3,890,185
Volume 9,233
Short Ratio
Av. Daily Volume 39,957
Stock charts supplied by TradingView

NewsSee all news

  1. aTyr Pharma to Participate in September Conferences

    SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  2. aTyr Pharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 final data presented October 5, 2017 at the International Annual Congress of the World Muscle Society (WMS).
Resolaris
Early onset facioscapulohumeral muscular dystrophy (FSHD)
Phase 1b/2 data released December 13, 2016 with further update at EASL April 2017.
Resolaris
Limb girdle muscular dystrophy (LGMD) 2B / Adult patients with facioscapulohumeral muscular dystrophy (FSHD)
Phase 1/2 interim data due 4Q 2019 with final data due mid-2020.
ATYR1923
Pulmonary sarcoidosis

Latest News

  1. aTyr Pharma to Participate in September Conferences

    SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today

  2. aTyr Pharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today